Why do cancer patients quit Life-Saving drugs? new study investigates
NCT ID NCT07443774
Summary
This study aims to understand why patients with early-stage, high-risk breast cancer stop taking their powerful new combination medications too soon. Researchers will follow 81 patients who are prescribed a standard hormone therapy pill plus a newer drug (like abemaciclib or ribociclib) to prevent cancer from coming back. The goal is to identify the real-world reasons for stopping treatment early—such as side effects or cost—to help future patients stay on their full course and improve survival.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CHU Grenoble Alpes
Grenoble, 38043, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.